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The carcinoma in situ (CIS) cell is the common precursor of nearly all testicular germ cell tumours (TGCT). In a previous study, we
examined the gene expression profile of CIS cells and found many features common to embryonic stem cells indicating that initiation
of neoplastic transformation into CIS occurs early during foetal life. Progression into an overt tumour, however, typically first happens
after puberty, where CIS cells transform into either a seminoma (SEM) or a nonseminoma (N-SEM). Here, we have compared the
genome-wide gene expression of CIS cells to that of testicular SEM and a sample containing a mixture of N-SEM components, and
analyse the data together with the previously published data on CIS. Genes showing expression in the SEM or N-SEM were selected,
in order to identify gene expression markers associated with the progression of CIS cells. The identified markers were verified by
reverse transcriptase–polymerase chain reaction and in situ hybridisation in a range of different TGCT samples. Verification showed
some interpatient variation, but combined analysis of a range of the identified markers may discriminate TGCT samples as SEMs or N-
SEMs. Of particular interest, we found that both DNMT3B (DNA (cytosine-5-)-methyltransferase 3 beta) and DNMT3L (DNA
(cytosine-5-)-methyltransferase 3 like) were overexpressed in the N-SEMs, indicating the epigenetic differences between N-SEMs
and classical SEM.
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The incidence of testicular germ cell tumours (TGCTs) has
increased markedly during the past decades, and although
accounting for only 1–2% of all cancers in men, TGCTs are now
the most common malignancy in the age group of 15–35 years old
men (Adami et al, 1994; Huyghe et al, 2003). Owing to a refined
treatment, in particular the introduction of cisplatin in combina-
tion chemotherapy, mortality rates have declined rapidly (Einhorn,
1981; Schmoll et al, 2004). Despite the high survival rate, still 4–
8% of relatively young patients die of the disease, especially those
with disseminated nonseminomas (N-SEM).
Testicular germ cell tumours comprise a heterogeneous group of
tumours, which are divided into two main histological subtypes,
classical seminoma (SEM) and N-SEMs. The N-SEM can be further
subdivided into choriocarcinoma, yolk sac tumour, embryonal
carcinoma and teratomas, and several of these components are
frequently present within one tumour. Despite the heterogeneity,
virtually all TGCTs originate from a common precursor, the
carcinoma in situ (CIS) cell (Skakkebaek, 1972), which is believed
to arise by transformation of a gonocyte (Skakkebaek et al, 1987),
and shows a striking similarity to embryonic stem cells at the gene
expression level (Almstrup et al, 2004). In addition, epidemiolo-
gical evidence (Moller, 1993; Bergstrom et al, 1996) and
comparative immunohistochemical studies of expressed proteins/
antigens (Rajpert-De Meyts et al, 2003) indicate that CIS is an
inborn lesion, probably arising in early foetal life and progressing
to an overt TGCT after puberty. The molecular mechanisms of the
initial malignant transformation into a CIS cell, and the
subsequent progression into overt tumours remains largely
unknown.
Gene expression studies provide a useful tool to identify
mechanistic pathways. A range of studies has recently reported
gene expression patterns in overt TGCT. Several studies have
focused on genes on chromosomes 17 and 12, because of frequent
rearrangements of these chromosomes (Skotheim et al, 2002;
Rodriguez et al, 2003; Skotheim and Lothe, 2003). One study
reported gene expression patterns of testicular SEM compared to
normal testicular parenchyma (Okada et al, 2003), and another
study have reported gene expression in SEM- and embryonic
carcinoma (EC)-derived cell lines (Sperger et al, 2003). Our
investigations have so far focussed on the preinvasive CIS stage of
TGCTs, and we have recently reported the genome-wide gene
expression profile of CIS (Almstrup et al, 2004; Hoei-Hansen et al,
2004a).
In order to investigate the transition from the preinvasive CIS
stage into overt tumours, we decided to analyse gene expression in
the two main types of overt TGCTs derived from CIS cells, SEM
and N-SEMs. We have used a microarray covering nearly the entire
human transcriptome to investigate differences in gene expression
between testicular tissue with CIS, a classical SEM and a N-SEM
containing a mixture of various tumour components (embryonal
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scarcinoma, yolk sac tumour and choriocarcinoma). The generated
expression profiles were analysed together with published data on
CIS using the same microarray (Almstrup et al, 2004). Identified
differentially expressed genes were further verified by reverse
transcriptase–polymerase chain reaction (RT–PCR) in a panel of
TGCT and the cellularity of the expression assessed by in situ
hybridisation (ISH). RT–PCR showed some interindividual
variation of expression, but the number of markers identified
allowed us to discriminate between SEM and N-SEM samples.
MATERIALS AND METHODS
Testicular tissues
The testicular tissue samples were obtained directly after
orchidectomy and macroscopic pathological evaluation. The
Regional Committee for Medical Research Ethics in Denmark
approved the use of the orchidectomy samples for the studies of
novel genes expressed in germ cell cancers. Samples of homo-
geneous overt testicular tumours were excised and divided into
several tissue fragments. Two to three fragments were snap-frozen
and stored at  801C for nucleic acid extraction, and several
adjacent fragments were fixed overnight at 41C in Stieve’s fluid or
paraformaldehyde (PFA), and then embedded in paraffin. Fixed
sections were subsequently stained with haematoxylin and eosin
(H&E) or by immunoperoxidase method for placental alkaline
phosphatase (ALPP or PLAP) (Giwercman et al, 1991), in order to
obtain the closest approximation of the histological content of the
samples.
Besides the histological classification of the adjacent fragments,
we also made imprints of the frozen fragments that specifically
were used for RNA isolation. This was an attempt to circumvent
the uncertainty about differences in cellularity between adjacent
biopsies from the same patient. After staining with ALPP (PLAP)
antibody, we could roughly confirm the histological observations
seen in the adjacent fragments (data not shown). A histological
description of all the used samples is presented in Table 1 with
abbreviated names.
Stimulation of differentiation in cell lines
Two established embryonal carcinoma-derived cell lines, NT2 and
2102Ep cells (Andrews, 1984), were grown in standard conditions
(5% CO2,3 7 1C). For analysis of the effect of retinoic acid (RA) on
gene expression, NT2 cells were grown in DMEM medium (10%
FBS, 2mML -glutamine, 25IUml
 1 penicillin, 25mgml
 1 strepto-
mycin) and stimulated with 10mM RA (Sigma-Aldrich, St Louis,
MO, USA) for 0–15 days to induce differentiation. 2102Ep cells
were grown in DMEM medium with added 100mM b-mercapto-
ethanol, and stimulated with 10mM RA for 0–10 days.
Microarray analysis
Isolation, labelling and hybridisation of testicular RNA was carried
out essentially as described before (Almstrup et al, 2004). In brief,
total RNA was purified using the NucleoSpin RNAII kit as
described by the manufacturer (Macherey-Nagel, Du ¨ren, Ger-
many) and analysed on a Bioanalyzer 2100 (Agilent Technologies,
Palo Alto, CA, USA). Samples of sufficient RNA quality were
linearly amplified using the RiboAmp RNA amplification kit
(Arcturus GmbH, Germany) and subsequently labelled with Cy3
and Cy5 using the Atlas Glass Fluorescent labelling kit (BD
Biosciences Clonetech, CA, USA). Labelled probes were cohybri-
dised to a 52000 element cDNA microarray representing the entire
Unigene database. Production of the microarray is described
elsewhere (http://embl-h3r.embl.de/). Slides were scanned on a
GenePix 4000B scanner (Axon Instruments, Union City, CA, USA)
and the generated images analysed in ChipSkipper (http://
chipskipper.embl.de/) using histogram segmentation. Unreliable
flagged spots and controls were taken out and quantified spots
were normalised using a framed median ratio centring
(frame¼200 genes). Each measurement relies on the average of
dye-swap experiments and spots that showed a big standard
deviation was sorted out. The data were analysed in the program
Genesis (Sturn et al, 2002) where clustering was carried out.
RT–PCR and ISH
In order to verify the results obtained from the microarray
analysis, expression of a selected set of genes, which in the
microarray analysis showed specific expression in either SEM or
N-SEM, was verified by RT–PCR and ISH. In addition, expression
of genes that could be associated with cell differentiation was
analysed by RT–PCR in the NT2 and 2102Ep cell lines with and
without RA treatment.
RT–PCR analysis was carried out essentially as described before
(Almstrup et al, 2004; Hoei-Hansen et al, 2004a). In brief, total
RNA was purified as described above, DNAse digested, and cDNA
Table 1 Histological description and abbreviated names of the samples used
Abbreviation RT–PCR Microarray Histology
50% CIS
a   Approximately 50% tubules with CIS and 50% tubules with normal spermatogenesis. From the vicinity of a SEM
75% CIS
a   Approximately 75% tubules with CIS and 25% tubules with normal spermatogenesis. From the vicinity of a SEM
100% CIS
a   Tissue containing almost entirely CIS. From the vicinity of an embryonal carcinoma
SEM   Homogeneous classical SEM
EC, TER, YS (N-SEM)    N-sem consisting of embryonal carcinoma, teratocarcinoma and yolk sac tumour
SEM1   Classical SEM with some connective tissue
SEM2   Classical SEM with some atrophy
SEM3   Homogeneous classical SEM
TER1   Teratoma
EC1   Embryonal carcinoma, homogeneous
EC2   Embryonal carcinoma and CIS with some necrosis
CIS1 (SEM)   100% tubules with CIS (in the vicinity of a SEM)
CIS2 (EC)   70% tubules with CIS (in the vicinity of an embryonal carcinoma)
CIS3   90% tubules with CIS without an overt tumour, but microinvasion, perhaps progressing to a SEM
CIS4   90% tubules with CIS without an overt tumour, but microinvasion, perhaps progressing to a N-SEM
NOR1   Normal, complete spermatogenesis from a patient with prostate cancer
NOR2   Normal, complete spermatogenesis from the vicinity of an embryonal carcinoma
RT–PCR¼reverse transcriptase–polymerase chain reaction; CIS¼carcinoma in situ; SEM¼seminoma; N-SEM¼nonseminoma; EC¼embryonic carcinoma.
aExpression
values of CIS vs normal are from Almstrup et al (2004).
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swas synthesised using a dT20 primer. Specific primers were
designed for each mRNA preferentially spanning intron–exon
boundaries to avoid amplification of genomic DNA. However, in
some cases additional primer pairs where both primers were
localised in the 30-exon were designed. PCR was performed in 30ml
of (final concentrations): 12mM Tris-HCl, pH 8.3; 50mM KCl;
1.9mM MgCl2; 0.1% Triton X-100; 0.005% gelatin; 250mM dNTP;
and 30pmol of each primer. H2O was used as a negative control,
and b-actin (ACTB) and b2-microglobulin (B2M) were used as
control of the PCR protocol. Cycle conditions: one cycle of 2min at
951C; 30–40 cycles (depending on the intensity of bands) of: 30s at
951C, 1min at 621C, 1min at 721C and finally one cycle of 5min at
721C. PCR products were run on 2% agarose gels and visualised by
ethidium bromide staining. In a few of the RT–PCR analyses of
less abundant transcripts, no bands were detectable after the first
round of PCR and nested primers were designed. A measure of 1ml
from the first PCR reaction was transferred to a new reaction
containing the nested primers and analysed as above with 10–20
additional cycles.
Nested primers with additional T3 or T7 extension were used to
generate PCR fragments, which subsequently were used in in vitro
transcription reactions to generate sense and antisense RNA
fragments used for the ISH as described before (Nielsen et al, 2003;
Almstrup et al, 2004; Hoei-Hansen et al, 2004a).
RESULTS
Comparison of CIS with SEM and N-SEM
We isolated testicular RNA from two patients characterised as
having a mixture of N-SEMs and a classical SEM, respectively, and
compared gene expression in these samples to each other and to a
sample from a patient classified as having CIS cells in all of the
seminiferous tubules (100% CIS) (see Table 1). A triangular design
was used and facilitated comparison between N-SEM vs 100% CIS,
SEM vs 100% CIS and N-SEM vs SEM. The 100% CIS sample had
previously been compared to a patient sample with complete and
normal spermatogenesis (Almstrup et al, 2004), and the CIS data
from this study were included in the subsequent data analysis.
Data were filtered to highlight genes up- or downregulated in
either the N-SEM or SEM as illustrated in Table 2. There was a
noticeable difference in the cutoff values used in the filtering
process to generate gene lists specific for either SEM or N-SEM. A
lower cutoff value (three-fold in the SEM group compared to five-
fold in the N-SEM group) was used to display a reasonable number
of SEM-specific genes. This lower cutoff value probably reflects the
fact that CIS cells are more similar to SEMs than N-SEMs (Nielsen
et al, 1974; Albrechtsen et al, 1982; Gondos, 1993). In addition to
the identification of genes specifically upregulated in SEM and N-
SEM, we in a similar manner searched for genes specifically
downregulated in each of the two tumour types, aiming at
identifying genes specifically downregulated during the invasive
transformation of CIS into a SEM or N-SEM, respectively.
The expression data of the selected genes were subjected to
hierarchical clustering with average linkage as shown in Figure 1.
In addition, a K-means clustering was made with K set to equal the
four filter groups. The K-means clustering nearly completely
resolved into the initial four filter groups, indicating a good
separation between the groups (Figure 1).
Verification by RT–PCR and ISH
In order to verify the results obtained from microarray analysis,
the expression of several differentially regulated genes was further
analysed by RT–PCR (Figure 2). This was performed on a
spectrum of different TGCTs to allow not only verification of the
expression in the samples used in the microarray analysis but also
in other specimens from patients with similar diagnosis (Figure 2;
Table 1). The results showed some variation, even between samples
with the same histological diagnosis. Differences in the cellularity
of the fragments used for RNA isolation may play a role in this, but
could not alone explain the observed variation, suggesting that
gene expression was variable also within samples from similar
tumour types. Bioinformatic searches in various databases (i.e.
http://www.ensembl.org/) revealed that for many loci additional
transcripts were described, including transcripts from both strands
(e.g. HLXB9, TAC3, SEC13, CHIT1 and COL22A), which could
influence the results. For most genes, we amplified PCR fragments
across splice sites in order to avoid amplification of genomic DNA,
but for some genes, we also applied primer pairs positioned
internally within the 30-exon (which typically corresponded to the
PCR fragment on the array). For many of the genes that were
assayed with both intron–exon spanning and 30-exon primer
pairs, different results were obtained (data not shown) substantiat-
ing the presence of multiple transcripts. Interestingly, we found a
high expression of fibrinogen beta B (FGB) gene in a sample of N-
SEM with various components, but not in pure EC or teratomas.
The cellularity of the expression was assayed by ISH (Figure 3).
In general, expression was localised to the neoplastic tissue.
However, in accordance with the presence of multiple transcripts,
we some times observed hybridisation signals in tissues that by
microarray and RT–PCR analysis appeared to have low or even
nondetectable expression of the gene (i.e. KIT; Figures 2A and 3A–
D). In addition, we occasionally observed hybridisation signals
from both the antisense and sense probes or only from the sense
probe. Together, this strongly suggests the presence of transcripts
derived from both strands and could indicate that results from
RT–PCR, ISH and microarray analyses were not always derived
from the same transcripts (see Discussion).
Expression in cell lines
In the RT–PCR analysis, we used two embryonal carcinoma cell
lines to investigate changes of expression related to tumour
differentiation (NT2 cells that differentiate after stimulation with
RA, and 2102Ep cells that do not differentiate upon RA addition).
For a few genes (i.e. KIT and IMAGE clone 770267), the expression
was affected by differentiation (Figure 2A).
DISCUSSION
This is the first study aimed at investigating genome-wide gene
expression changes during progression from preinvasive CIS to
overt TGCTs. The results showed some interpatient variation, and
a relatively small number of genes were differentially expressed
between SEM and N-SEM was identified. This was probably caused
by the experimental design of the microarray study as it only
included one sample from each tumour type. The subsequent RT–
PCR and ISH analysis on a range of samples showed some
interpatient variation (Figures 2 and 3), especially for the
Table 2 Filtering of data to display genes specifically regulated in SEM
and N-SEM compared to CIS
Experiment Up in SEM Up in N-SEM
Down
in SEM
Down in
N-SEM
N-SEM vs 100% CIS o2 45 42 o0.5
SEM vs 100% CIS 43 o2 o0.5 42
SEM vs N-SEM 42 o0.5 o0.5 42
100% CIS vs Normal
a o2 and 40.5 o2 and 40.5 42 42
CIS¼carcinoma in situ; SEM¼seminoma; N-SEM¼nonseminoma.
aFrom Almstrup
et al (2004).
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snonseminomatous tumours. Similar variation in gene expression
between testicular SEMs has been reported earlier (Okada et al,
2003). In the study by Okada et al (2003), the criterion for a SEM
marker was an upregulation in just seven out of 13 microdissected
SEM samples investigated. Their subsequent RT–PCR verification
showed a variation similar to the one we have observed here, both
200018 TClA  H. sapiens mRNA for T-cell leukaemia/lymphoma 1
2305046
48417 FRCP2 FRCP2 likely orthologue of mouse fibronectin type III repeat containing protien 2
48417 FRCP2 FRCP2 likely orthologue of mouse fibronectin type III repeat containing protien 2
1691575 COL22A1 COL22A1 collagen, type XXII, alpha 1
2151705 HLXB9 HLXB9 homeo box HB9
2255411 ESTs, highly similar to AF 198488 1 transcription factor LBP-9 [H. sapiens]
269016 KIT Human KIT protien and alternatively spliced KIT protien {KIT} gene, complete cds
1519951 
274643
269968 Hypothetical protien LOC92312
127962 Homo sapiens cDNA FLJ22.539 fis,clone HRC13227
293111 UNG Human cDNA for uracil-DNA glycosylase
740416 SOX17 SRY (sex deterimining region Y)-box 17
38108 PRO1914 PRO1914 protien
49311 MLL2 myeloid/lymphoid or mixed-lineage leukaemia 2
2170585 
1733629 GPHA2 glycoprotien hormone alpha2
35325 SH2D1A gene for SH2 domain protien 1A, Duncan's disease
161857
767877
342164
2214075 
1509522 
31971 KIAA0363 Human mRNA for KIAA0363 gene,partial cds
327480 Homo sapiens mRNA cDNA DKFZp434K0621 (from clone DKFZp434K0621) partial cds
2062816 Hypothetiacal protien LOC200213
1056129
21910 Human femitin L chain mRNA, complete cds
52650
936278
1837520 Homo sapiens transcribed sequence with moderate similarity to protein pir: S52491 polyadenylate binding protein II − human
1030921
925427
726522 Homo sapiens similar to Envoplakin (210 kDa paraneoplastic pemphigus antigen) (p210)
1707107 CHIT1 human chitotriosidase Precursor mRNA, complete cds
2304770
1644768 GOLGA6 Golgi autoantigen, golgin subfamily a, member 6
1644768 
796313 
299603 
344373 
742576 SPAG11 H. sapiens HE2 mRNA
2304733
22040 MMP9 human type IV collagenase mRNA, complete cds
484960 LOC148898 hypothetical protein BC007899
1844282 Transglutaminase 3 (E polypeptide, protein−glutamine−gamma-glutamyttransferase)
814236
396839
428442 TAC3 tachykinin 3 (neuromedin K, neurokinin beta)
1712105 AF5Q31 ALL 1 fused gene from 5q31
2163456
191050
460940
2323438
279219 C20orf58 chromosome 20 open-reading frame 58
50008 Homo sapiens similar to RIKEN cDNA 1500004O14 (LOC352669). mRNA
38015 ESTs. weakly similar to KIAA0918 protein (H. sapiens)
1940318 KIAA0184 KIAA0184 protein
193411 ORM1, ORM2 human mRNA for alpha1-acid glycoprotein (orosomucoid)
122136
116691 
116691 
484915 RBM5 RNA binding motif protein 5
260215 Homo sapiens cDNA FLJ31733 fis, clone NT2R12006943
2338548 CHIT1 chitinase 1 (chitotriosidase)
982738
323623 DKFZP564O1863 DKFZP564O1863 protein
2337492
1645164 Hypothetical protein LOC340094
2179475 PLA2G2D phospholipase A2, group IID
23877 ATP8A1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1
258898 SFRP2 Homo sapiens secreted frizzled-related protein 2 (SFRP2), mRNA
1639650
796831 PHEX human metalloendopeptidase homolog (PEX) mRNA, complete sequence
984870 Similar to ankylosis, progressive homolog
2262600
2185733 S100A14 S100 calcium binding protein A14
968435 TDGF1 TDGF1 teratocarcinoma-derived growth factor 1 (cripto)
276915 DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta
247564 Homo sapiens transcribed sequence with moderate similarity to protein ref:NP_060190.1 (H. sapiens) hypothetical protein FLJ20234
770267
2310214
760230 AGR2 Homo sapiens secreted cement gland protein XAG-2 homolog (hAG-2/R) mRNA, complete cds
2239712 Homo sapiens transcribed sequence with weak similarity to protein ref:NP_038602.1 (M. musculus) L1 repeat. Tf subfamily. member 18
195698 FGB human fibrinogen beta chain gene, complete mRNA
1948588 DNMT3L DNA (cytosine-5-)-methyltransferase 3 like
724358 KRT19 keratin 19
2223461 TM4SF3 transmembrane 4 superfamily member 3
345522 SEC13-like 1 (S. cerevisiae)
2229297 
488962 EBAF endometrial bleeding-associated factor (left−right determination, factor A: transforming growth factor beta superfamily)
357967 KIAA1712 KIAA1712 protein
357847 CCDC2 coiled-coil domian containing 2
357848 Homo sapiens similar to hypothetical protein FLJ20958 (LOC285177). mRNA
1870935 FN1 fibronectin 1
327085 DLGAP1 discs, large (Drosophila) homolgue-associated protein 1
296601 CD163 H. sapiens mRNA for M130 antigen cytoplasmic variant 2
2243068
2365824
47615 HLA-B human MHC HLA-B7 class I cell surface glycorprotein heavy-chain mRNA, complete cds
2446243
208806 TTR human serum prealbumin gene, complete cds
366038 
242630 APOA2 human mRNA for apolipoprotein ALL precursor
2130177 
375860 
1752104 
451838 
1988620 
2461158 
2032251 C4orf7 chromosome 4 open-reading frame 7
2185475 
1964547 
276835 TPARL TPA-regulated locus
2239324 CCKBR cholecystokinin B receptor
2010143
244875 CBS human cystathionine-beta-synthase (CBS) mRNA
1571370 Homo sapiens transcribed sequence with moderate similarity to protein pir:S30392 (H. sapiens) S30392 phospholipase A2 homolog
2028930 ESTs, Moderately similar to JE0065 retroviral proteinase-like protein (H. sapiens)
1637617 STELLA similar to PGC7
2173015 CDX2 Homo sapiens caudal-type homeobox gene 2 (CDX2) sequence
140997 PLAB Homo sapiens pre−pro placental TGF-beta gene, complete cds
898574 
195662 CDH1 cadherin 1, type 1, E-cadherin (epithelial)
1597546 MGC10818 hypothetical protein MGC10818 
342941 APLN APLN apelin
2131469 ETS2 ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
114388 
2229342 FLJ10808 hypothetical protein FLJ10808
2304122
212398
343404 Homo sapiens clone 24841 mRNA sequence
767055 
754101 FLJ14440 thromobospondin
149319 
24838 Homo sapiens clone 24838 mRNA sequence
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Figure 1 Hierarchical and K-means clustering of genes expressed specifically in testicular SEM or N-SEM. Results from the microarray analysis were
filtered to show genes whose expression would discriminate between the two overt tumour types. This list was then subjected to hierarchical and K-means
clustering (K was set to 4 according to the number of groups filtered for) using Euclidian distance measures. The clustering was carried out using the Genesis
software (Sturn et al, 2002). Results on the CIS samples are from Almstrup et al (2004).
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sin SEMs and N-SEMs, suggesting that the phenotypic plasticity is
an intrinsic feature of TGCTs. Many of the genes that showed
interpatient variation are listed in databases (i.e. http://www.
ensembl.org/), with ESTs on both strands illustrating that there are
expressed transcripts that do not correspond to the known genes
in these regions. This is consistent with recent reports on
widespread expression of transcripts from both strands in large
parts of the human genome (Kapranov et al, 2002; Cawley et al,
2004), and we speculate that this feature may contribute to the
heterogeneity of overt tumours – especially N-SEMs. Even protein
expression has earlier been reported to be markedly heterogeneous
in TGCTs, including CIS (Rajpert-De Meyts et al, 1996; Lifschitz-
Mercer et al, 2002; Hoei-Hansen et al, 2004b; Kato et al, 2004). It is,
however, evident from the RT–PCR results shown in Figure 2 that
by combining results from a range of different genes, a TGCT
sample could be classified as a SEM or N-SEM.
The CIS samples included in the microarray data analysis
originated from tissue next to different overt tumours (Almstrup
et al, 2004). It has been suggested that CIS cells next to SEMs and
N-SEMs might be different (Oosterhuis et al, 1993; Rajpert-De
Meyts et al, 1996). The reported expression in CIS is not specific
for CIS cells next to a specific tumour type but represents an
‘average’ if differences exist between the analysed CIS samples.
Some of the genes identified here have earlier been reported as
differentially expressed (mainly at the protein level) along with CIS
progression into overt tumours. An example of a gene with
differential expression in various TGCTs is the v-kit Hardy–
Zuckerman 4 feline sarcoma viral oncogene homologue, better
known as KIT. The KIT protein is in most cases found expressed in
CIS and SEM, but not in N-SEMs, with an exception of
undifferentiated somatic elements that sometimes can be present
in teratomas (Strohmeyer et al, 1991; Rajpert-De Meyts and
Skakkebaek, 1994). KIT has, however, also been reported to be
expressed in one-third of N-SEMs (Izquierdo et al, 1995),
reflecting the heterogeneity of these tumours. In our microarray
analysis, we found KIT in the ‘Down in N-SEM’ group (Figure 1),
and the RT–PCR analysis in tumour samples confirmed this
expression pattern (Figure 2A). However, a band was observed in
the EC/TER/YST sample (Figure 2A), but not in the pure EC
samples whereto ISH on the contrary revealed a faint hybridisation
(Figure 3D; the samples used for RT–PCR and ISH were not from
the same patient). On the other hand, a strong expression of KIT
was observed in a partially keratinised epithelial component of
teratoma (Figure 3B). There might be differences between
expression of the KIT transcript and the reported protein
expression, but the results most probably reflect the heterogeneity
of N-SEMs.
In the ‘Up in N-SEM’ group (Figure 1), we found a range of
genes known to be highly expressed in embryonic stem cells and
EC cell lines and important for proper early development. These
genes include STELLA, CDX2, TDGF1 (Cripto) and EBAF, and
emphasise the embryonic features of the N-SEMs. However, none
were highly expressed in CIS cells (Almstrup et al, 2004), and thus
apparently discriminate the embryonic features of CIS cells and N-
SEMs. In addition, we identified a high expression of FGB gene,
which may be a new marker for yolk sac tumour component of
mixed TGCTs (Figures 1 and 2).
Gene expression in EC and SEM cell lines compared to
embryonic stem cell lines has been described by Sperger et al
(2003) and their results show some overlap with the genes we
have identified. These include in the N-SEM (EC) group, CBS and
DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), and in the
SEM group, LBP-9, KIT, TCL1A, FRCP2 and MMP9.I ti s
important, however, to keep in mind that Sperger et al identified
genes specific for TGCT-derived cell lines compared to somatic
cell lines and normal testis, whereas we compared expression in
SEM and N-SEM against their precursor CIS cells. Therefore,
our analysis did not identify some tumour markers such as
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Figure 2 Verification of the microarray data by RT–PCR. RT–PCR primers for selected genes were used on a panel of different testicular tissue samples
and cell lines. Gene-specific primers were designed preferentially to span intron–exon boundaries. The genes were divided according to the microarray
analysis into: (A) Genes preferentially overexpressed in SEMs and (B) genes preferentially overexpressed in N-SEM. At the lower part of the figure,
expression of ACTB is shown as a control of the RT–PCR protocol. Sample abbreviations can be found in Table 1, except for: M¼100bp marker,
H2O¼control, NT2¼NT2 cell line days 0–15 after RA treatment, 2102Ep¼2102Ep cell line days 0–10 after RA treatment.
Gene expression profiling of germ cell cancer progression
K Almstrup et al
1938
British Journal of Cancer (2005) 92(10), 1934–1941 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sPOU5F1, FLJ10884 and AK3, because they already were upregu-
lated in the CIS cells. The difference in the experimental set-up
thus probably largely explains the differences in the identified
markers.
Interestingly, DNMT3B and DNA (cytosine-5-)-methyltransfer-
ase 3 like (DNMT3L), which are involved in the establishment of
global DNA methylation in the mammalian genome (Burgers et al,
2002), were both found in the ‘Up in N-SEM’ group in the
Figure 3 Identification of the expressing cell types by ISH. In situ hybridisation was performed with antisense and control sense (inserted images) RNA
probes. Expression is shown for three genes: KIT (A–D), HLXB9 (E–H), and the IMAGE clone number 260215 (I–M). KIT was highly expressed in CIS
cells (A) and in SEM (C), and present in components of teratoma, for example, keratinised intestine-like epithelium as shown here (B) and embryonal
carcinoma (D). HLXB9 expression was high in CIS cells (EþF) and SEM (G); HLXB9 was present in embryonal carcinoma tumour components (H) and it
was detected in spermatocytes, spermatids and Leydig cells in normal testicular tissue (E). IMAGE clone 260215 was present in spermatocytes, spermatids
and Sertoli cells in normal testicular tissue (I); the expression in Sertoli cells was confirmed in a tubule with Sertoli cell-only pattern (J). Additionally, the
transcript was highly expressed in CIS cells (K) and present in SEM (L) and components of embryonal carcinoma (M). Scale bar represents 50mm.
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smicroarray analysis (Figure 1). The RT–PCR analysis verified the
upregulation of DNMT3B in N-SEM samples, but not in the
teratoma sample, suggesting that the signal originated from
undifferentiated components such as EC (Figure 2). This is in
line with previously described differences in the epigenetic
phenotype of SEMs and N-SEMs. The genome of N-SEMs appears
to be more methylated than that of both CIS and SEMs (Smiraglia
et al, 2002; Smith-Sorensen et al, 2002; Honorio et al, 2003).
Teratomas are more differentiated than EC and the absence of
DMNT3L expression in teratomas in the RT–PCR analysis could
indicate that a demethylation of DNA occurs when an EC
differentiates into a teratoma.
The differential expression of DNA methyltransferases suggests
that there may be epigenetic differences between the SEM and N-
SEMs, which could play a central role in the progression of CIS cell
into the different TGCT subtypes. If changes in methylation are
implicated in the transformation into N-SEMs, demethylation
could be highly tumour specific. On the cellular level, chromoso-
mal region-specific demethylation may open for transcription of
multiple transcripts from the same locus, which then could lead to
the observed presence of multiple overlapping transcripts.
Combining the verified results of previous studies and the
verified findings of our current investigation allows identification
of a distinct gene expression ‘signature’ of classical SEM in
comparison to N-SEM. Genes/antigens preferentially expressed in
SEM include PLAP (Hofmann et al, 1989), M2A (Marks et al,
1995), KIT (Strohmeyer et al, 1991; Rajpert-De Meyts and
Skakkebaek, 1994; this study), cyclin D2 (CCND2) (Houldsworth
et al, 1997; Bartkova et al, 1999; Okada et al, 2003), MAGE-A4
(Aubry et al, 2001), HIWI (Qiao et al, 2002), DAZL-1 (Lifschitz-
Mercer et al, 2002), TFCP2L1 (this study), Aggrus (Kato et al, 2004)
and JUP (Skotheim et al, 2003). The emerging expression pattern
of N-SEMs is more complex, and because of histological variability
of these tumours, a distinct ‘signature’ may not exist for this entity.
The heterogeneity is especially prominent in teratomas, which
express variable somatic cell-specific genes, and each component
of the teratoma has to be studied separately. The undifferentiated
EC and EC-derived cell lines have been more thoroughly
investigated. A number of proteins highly expressed in EC are
related to pluripotency, for example, POU5F1 (OCT-4) (Looijenga
et al, 2003) and TFAP2C (Hoei-Hansen et al, 2004b), and are
equally highly expressed in SEM. It is important to remember that
the genes we have identified here are differentially expressed
between both CIS, SEM and N-SEM. The list of genes/antigens
expressed preferentially in EC vs SEM is thus rather short and only
includes TRA-1–60 (Andrews et al, 1984), KRT19 and DNMT3L
(this study).
In conclusion, we have identified gene expression markers of the
two major subtypes of TGCT and compared them to the gene
expression profile of CIS using a genome-wide microarray.
Identified markers were verified with both RT–PCR and ISH on
a range of TGCT samples. Verification showed some interpatient
variation, which is similar to that found in other studies, but when
a range of genes was investigated, discrimination between the two
tumour types was possible. The function of some of the identified
genes confirmed that epigenetic differences exist between the
major TGCT subtypes, the N-SEMs and SEMs, and that epigenetic
factors most probably contribute to the phenotypic plasticity of
TGCTs. It is, however, clear that we are only at the beginning of the
road, and the understanding of the mechanism of neoplastic
transformation and invasive progression of germ cell neoplasms
requires further research.
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